Renal medullary carcinoma: Prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement

Medical and Pediatric Oncology

Volumn 33, Issue 6, 1999, Pages 551-557

  Stahlschmidt, Jens ^a   Cullinane, Catherine ^a   Roberts, Paul ^a   Picton, Susan V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Child; Cytogenetics; Histopathology; Renal neoplasm; Treatment

Indexed keywords

BCR ABL PROTEIN; CISPLATIN; METHOTREXATE; VINBLASTINE;

ADOLESCENT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CYTOGENETICS; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY MEDULLA; MALE; PRIORITY JOURNAL; REMISSION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MEDULLARY; FATAL OUTCOME; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; KIDNEY NEOPLASMS; MALE; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC;

EID: 0032759172     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199912)33:6<551::AID-MPO5>3.0.CO;2-5     Document Type: Article

References (25)

1. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19:1-11.
2. Avery RA, Harris JE, Davis CJ Jr, et al. Renal medullary carcinoma: clinical and therapeutic aspects of a newly described tumor. Cancer 1996;78:128-132.
3. Friedrichs P, Lassen P, Canby E, Graham C. Renal medullary carcinoma and sickle cell trait. J Urol 1997;157:1349.
4. Kalyanpur A, Schwartz DS, Fields JM, et al. Renal medulla carcinoma in white adolescent. AJR 1997;169:1037-1038.
5. Adsay NV, deRoux SJ, Sakr W, Grignon D. Cancer as a marker of genetic medical disease: an unusual case of medullary carcinoma of the kidney. Am J Surg Pathol 1998;22:260-264.
6. Coogan CL, McKiel CF, Flanagan MJ, et al. Renal medullary carcinoma in patients with sickle cell trait. Urology 1998;51: 1049-1050.
7. Pickhardt PJ. Renal medullary carcinoma: an aggressive neoplasm in patients with sickle cell trait. Abdom Imaging 1998;23:531-532.
8. Larson DM, Gilstad CW, Manson GW, Henry MR. Renal medullary carcinoma: report of a case with positive urinary cytology. Diagn Cytopathol 1998;18:276-279.
9. Wesche WA, Wilimas J, Khare V, Parham DM. Renal medullary carcinoma: a potential sickle cell nephropathy of children and adolescents. Pediatr Pathol Lab Med 1998;18:97-113.
10. Pirich LM, Chou P, Walterhouse DO. Prolonged survival of a patient with sickle cell trait and metastatic renal medullary carcinoma. J Pediatr Hematol Oncol 1999;21:67-69.
11. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
12. Rodriguez-Jurado R, Gonzalez-Crussi F. Renal medullary carcinoma. J Urol Pathol 1996;4:191-203.
13. Schaafsma HE, Ramaekers FCS, van Muijen GNP, et al. Distribution of cytokeratin polypeptides in human transitional carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Surg Pathol 1990;136:329-343.
14. Purkis PE, Steel JB, Mackenzie IC, et al. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990;97:39-50.
15. Harnden P, Southgate J. Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinoma. J Clin Pathol 1997; 50:1032-1033.
16. Moll R, Loewe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. Am J Pathol 1992;140:427-447.
17. Dierick AM, Praet M, Roels H, et al. Vimentin expression of renal cell carcinoma in relation to DNA content and histological grading: a combined light microscopic, immunocytochemical and cytophotometrical analysis. Histopathology 1991;18:315-322.
18. Parham DM, Morton K, Coghill G, et al. Expression of CD15 antigen in urinary bladder transitional cell carcinoma. J Clin Pathol 1990;43:541-543.
19. Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surv 1992;15:105-118.
20. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996;88:386-401.
21. Lee CCR, Yamamoto S, Morimura K, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathological features. Cancer 1997;79:781-789.
22. Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by bcl-2. Proc Natl Acad Sci USA 1995; 92:5287-5291.
23. Rosty C, Martine P, Zucman J, et al. Cytogenetic and molecular analysis of a t(1;22)(p36;q11.2) in a rhabdoid tumour with a putative homozygous deletion of chromosome 22. Genes Chrom Cancer 1998;21:82-89.
24. Sawyer JR, Goosen LS, Swanson CM, et al. A new reciprocal translocation (12;22)(q24.3;q11.2-12) in a malignant rhabdoid tumour of the brain. Cancer Genet Cytogenet 1998;101:62-67.
25. Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1985;133:402-407.